PMID- 34966643
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220429
IS  - 2225-0719 (Print)
IS  - 2310-8819 (Electronic)
IS  - 2225-0719 (Linking)
VI  - 9
IP  - 6
DP  - 2021 Dec 28
TI  - Identification and Validation of an Immune-related Prognostic Signature for 
      Hepatocellular Carcinoma.
PG  - 798-808
LID - 10.14218/JCTH.2021.00017 [doi]
AB  - BACKGROUND AND AIMS: The immune system plays vital roles in hepatocellular 
      carcinoma (HCC) initiation and progression. The present study aimed to construct 
      an immune-gene related prognostic signature (IRPS) for predicting the prognosis 
      of HCC patients. METHODS: Gene expression data were retrieved from The Cancer 
      Genome Atlas database. The IRPS was established via least absolute shrinkage and 
      selection operator (LASSO) and multivariate Cox regression analysis. The 
      prognostic values of the IRPS were further validated using the International 
      Cancer Genome Consortium (ICGC) dataset. RESULTS: A total of 62 genes were 
      identified as candidate immune-related prognostic genes. According to the results 
      of Lasso and multivariate Cox regression analysis, we established an IRPS and 
      confirmed its stability and reliability in the ICGC dataset. The IRPS was 
      significantly associated with advanced clinicopathological characteristics. Both 
      Cox regression analyses revealed that the IRPS could be independent risk factors 
      influencing prognosis of HCC patients. The relationships between the IRPS and 
      infiltration of immune cells demonstrated that the IRPS was associated with 
      immune cell infiltration. Furthermore, a nomogram was constructed to estimate the 
      survival probability of HCC patients. CONCLUSIONS: The IRPS was effective for 
      predicting prognosis of HCC patients, which might serve as novel prognostic and 
      therapeutic biomarkers for HCC.
CI  - (c) 2021 Authors.
FAU - Xia, Xinxin
AU  - Xia X
AUID- ORCID: 0000-0001-5897-3559
AD  - Department of Traditional Chinese Medicine, The First Affiliated Hospital of 
      Xi'an Jiaotong University, Xi'an, Shaanxi, China.
FAU - Tang, Ping
AU  - Tang P
AUID- ORCID: 0000-0002-3667-8409
AD  - Department of Oncology, The Third Affiliated Hospital of Hunan University of 
      Chinese Medicine, Zhuzhou, Hunan, China.
AD  - Department of Oncology, The First Affiliated Hospital of Hunan College of 
      Traditional Chinese Medicine, Zhuzhou, Hunan, China.
FAU - Liu, Hui
AU  - Liu H
AUID- ORCID: 0000-0001-6559-1380
AD  - Department of Breast Surgery, The First Hospital of Hunan University of Chinese 
      Medicine, Changsha, Hunan, China.
FAU - Li, Yuejun
AU  - Li Y
AUID- ORCID: 0000-0001-5714-2323
AD  - Department of Oncology, The Third Affiliated Hospital of Hunan University of 
      Chinese Medicine, Zhuzhou, Hunan, China.
AD  - Department of Oncology, The First Affiliated Hospital of Hunan College of 
      Traditional Chinese Medicine, Zhuzhou, Hunan, China.
LA  - eng
PT  - Journal Article
DEP - 20210817
PL  - United States
TA  - J Clin Transl Hepatol
JT  - Journal of clinical and translational hepatology
JID - 101649815
PMC - PMC8666365
OTO - NOTNLM
OT  - Hepatocellular carcinoma
OT  - Immune-related gene
OT  - Prognostic signature
COIS- The authors have no conflict of interests related to this publication.
EDAT- 2021/12/31 06:00
MHDA- 2021/12/31 06:01
PMCR- 2021/08/17
CRDT- 2021/12/30 05:41
PHST- 2021/01/08 00:00 [received]
PHST- 2021/05/01 00:00 [revised]
PHST- 2021/07/17 00:00 [accepted]
PHST- 2021/12/30 05:41 [entrez]
PHST- 2021/12/31 06:00 [pubmed]
PHST- 2021/12/31 06:01 [medline]
PHST- 2021/08/17 00:00 [pmc-release]
AID - JCTH.2021.00017 [pii]
AID - 10.14218/JCTH.2021.00017 [doi]
PST - ppublish
SO  - J Clin Transl Hepatol. 2021 Dec 28;9(6):798-808. doi: 10.14218/JCTH.2021.00017. 
      Epub 2021 Aug 17.